Literature DB >> 8400231

Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.

U Budde1, R E Scharf, P Franke, K Hartmann-Budde, J Dent, Z M Ruggeri.   

Abstract

Twelve of 19 patients with myeloproliferative disorders showed a decrease of absence of the largest multimers of plasma von Willebrand factor (vWF) that correlated with elevated platelet counts but not with leukocyte counts. This suggested that platelets, rather than leukocytes, may be associated with the pathogenesis of the acquired vWF abnormality seen in these patients. To examine the hypothesis further, we studied 12 patients with reactive thrombocytosis after splenectomy. Increased platelet count (> 5 x 10(11)/L) after splenectomy was associated with vWF abnormalities indistinguishable from those detected in patients with myeloproliferative disorders. Accordingly, there was an inverse correlation between proportion of large vWF multimers and platelet, but not leukocyte, number: normalization of the platelet count was accompanied by restoration of a normal vWF multimeric pattern. These findings suggest that an increase in the number of platelets circulating in blood may favor the adsorption of larger vWF multimers onto the platelet membrane, resulting in their removal from the circulation and subsequent degradation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400231

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  A Study of Haemostatic Parameters in Patients of Chronic Myeloid Leukaemia.

Authors:  Ankur Jain; Naresh Gupta; Tejinder Singh; Sunita Agarwal
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Authors:  Lamia Lamrani; Catherine Lacout; Véronique Ollivier; Cécile V Denis; Elizabeth Gardiner; Benoit Ho Tin Noe; William Vainchenker; Jean-Luc Villeval; Martine Jandrot-Perrus
Journal:  Blood       Date:  2014-06-20       Impact factor: 22.113

3.  Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized.

Authors: 
Journal:  P T       Date:  2010-01

Review 4.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 5.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

6.  Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes.

Authors:  Amihai Rottenstreich; Geffen Kleinstern; Galia Spectre; Nael Da'as; Esther Ziv; Yosef Kalish
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

Review 7.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

Review 8.  Hemostatic changes in patients with malignancy.

Authors:  G H Goldsmith
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 9.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

10.  Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.

Authors:  P J van Genderen; J J Michiels; S C van der Poel-van de Luytgaarde; H H van Vliet
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.